What SEC filings does Boston Scientific Corporation submit to the SEC?

Boston Scientific Corporation (BSX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about BSX?

A Form 4 for BSX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Boston Scientific Corporation?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for BSX?

The 10-K is Boston Scientific Corporation's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all BSX SEC filings directly on EDGAR?

You can view all historical Boston Scientific Corporation filings on the SEC EDGAR company page for BSX. Each filing card on this page links directly to the original SEC document.

How often does Boston Scientific Corporation file with the SEC?

Boston Scientific Corporation files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling BSX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

BSX SEC Filing News — Boston Scientific Corporation

Latest SEC filings for Boston Scientific Corporation (BSX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-07.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary syst…

Sector: Healthcare Industry: Medical Devices Market Cap: $64.3B CIK: 885725

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for BSX currently lean bullish. Of the 20 displayed SEC filing records, 7 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 13 insider transactions (Form 4) in this period.

BSX Filing Activity Snapshot 2026-05-21 — 2026-10-07

Insider Transactions (Form 4)

7 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$9.00M

Mahoney Michael F (Director, Chairman, President & CEO) · 2026-08-05

186,240 shares · Form 4

Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Boston Scientific Corporation.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 7 open-market purchase, 3 other reported transaction, 2 option exercise and 1 gift. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×7: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Other reported transaction ×3: The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.
Option exercise ×2: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Form 4 Option exercise Tax / Compensation Filing 2026-09-03

BSX insider Form 4 filed for equity award, exercise, or tax withholding

O'Connor Padraig Andrew (EVP, Global Operations) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,171	—	—
`F`	Tax withholding on vested shares	567	$48.37	$27.4K
`M`	Option exercise derivative · Restricted Stock Units	1,171	—	—

Filing: Form 4 (Insider Transaction) Insider: O'Connor Padraig Andrew (EVP, Global Operations) Shares: 1,738

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-26

BSX insider Morano Susan E (Director) bought 2,040 shares (~$100.4K)

Morano Susan E, listed as Director at BOSTON SCIENTIFIC CORP, reported an open-market purchase of 2,040 BSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	2,040	$49.22	$100.4K

Filing: Form 4 (Insider Transaction) Insider: Morano Susan E (Director) Shares: 2,040 Est. Value: $100.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-08-12

BSX insider Form 4 filed for equity award, exercise, or tax withholding

Woodworth Emily (SVP, Global Controller and CAO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`I`	Discretionary transaction	2,930	$51.19	$150.0K

Filing: Form 4 (Insider Transaction) Insider: Woodworth Emily (SVP, Global Controller and CAO) Shares: 2,930

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-08-11

BSX insider Form 4 filed for equity award, exercise, or tax withholding

Monson Jonathan (EVP and CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`I`	Discretionary transaction	9,908	$50.46	$500.0K

Filing: Form 4 (Insider Transaction) Insider: Monson Jonathan (EVP and CFO) Shares: 9,908

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-07

BSX insider Habiger David C (Director) bought 2,100 shares (~$99.9K)

Habiger David C, listed as Director at BOSTON SCIENTIFIC CORP, reported an open-market purchase of 2,100 BSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	2,100	$47.59	$99.9K

Filing: Form 4 (Insider Transaction) Insider: Habiger David C (Director) Shares: 2,100 Est. Value: $99.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-05

BSX insider Habiger David C (Director) bought 1,182 shares (~$56.9K)

Habiger David C, listed as Director at BOSTON SCIENTIFIC CORP, reported an open-market purchase of 1,182 BSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,042	$48.07	$50.1K
`P`	Open-market purchase	140	$48.59	$6.8K

Filing: Form 4 (Insider Transaction) Insider: Habiger David C (Director) Shares: 1,182 Est. Value: $56.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-05

BSX insider Mahoney Michael F (Director, Chairman, President & CEO) bought 186,240 shares (~$9.00M)

Mahoney Michael F, listed as Director, Chairman, President & CEO at BOSTON SCIENTIFIC CORP, reported an open-market purchase of 186,240 BSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	186,240	$48.33	$9.00M
`I`	Discretionary transaction	22,119	$48.43	$1.07M

Filing: Form 4 (Insider Transaction) Insider: Mahoney Michael F (Director, Chairman, President & CEO) Shares: 186,240 Est. Value: $9.00M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-03

BSX insider LUDWIG EDWARD J (Director) bought 5,000 shares (~$227.4K)

LUDWIG EDWARD J, listed as Director at BOSTON SCIENTIFIC CORP, reported an open-market purchase of 5,000 BSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	5,000	$45.48	$227.4K

Filing: Form 4 (Insider Transaction) Insider: LUDWIG EDWARD J (Director) Shares: 5,000 Est. Value: $227.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-08-03

BSX insider Form 4 filed for equity award, exercise, or tax withholding

Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`I`	Discretionary transaction	64,198	$46.73	$3.00M

Filing: Form 4 (Insider Transaction) Insider: Fitzgerald Joseph Michael (EVP & Group Pres, Cardiology) Shares: 64,198

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-07-02

BSX insider Form 4 filed for equity award, exercise, or tax withholding

Monson Jonathan (EVP and CFO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,087	—	—
`F`	Tax withholding on vested shares	1,010	$43.06	$43.5K
`M`	Option exercise derivative · Restricted Stock Units	2,087	—	—

Filing: Form 4 (Insider Transaction) Insider: Monson Jonathan (EVP and CFO) Shares: 3,097

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-06-01

BSX insider Form 4 filed for equity award, exercise, or tax withholding

Mahoney Michael F (Director, Chairman, President & CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	386,755	—	—

Filing: Form 4 (Insider Transaction) Insider: Mahoney Michael F (Director, Chairman, President & CEO) Shares: 386,755

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-21

BSX insider Pegus Cheryl (Director) bought 1,770 shares (~$100.0K)

Pegus Cheryl, listed as Director at BOSTON SCIENTIFIC CORP, reported an open-market purchase of 1,770 BSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,770	$56.49	$100.0K

Filing: Form 4 (Insider Transaction) Insider: Pegus Cheryl (Director) Shares: 1,770 Est. Value: $100.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-21

BSX insider LUDWIG EDWARD J (Director) bought 3,580 shares (~$202.9K)

LUDWIG EDWARD J, listed as Director at BOSTON SCIENTIFIC CORP, reported an open-market purchase of 3,580 BSX shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	3,580	$56.68	$202.9K

Filing: Form 4 (Insider Transaction) Insider: LUDWIG EDWARD J (Director) Shares: 3,580 Est. Value: $202.9K

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for Boston Scientific Corporation. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-07

BSX filed 8-K — material company event

BOSTON SCIENTIFIC CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-23

BSX filed 8-K — material company event

BOSTON SCIENTIFIC CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-08

BSX filed 8-K — material company event

BOSTON SCIENTIFIC CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-26

BSX filed 8-K — material company event

BOSTON SCIENTIFIC CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-29

BSX filed 8-K — material company event

BOSTON SCIENTIFIC CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-27

BSX filed 8-K — material company event

BOSTON SCIENTIFIC CORP filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Boston Scientific Corporation.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-03

BSX filed Quarterly Report (10-Q)

BOSTON SCIENTIFIC CORP filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Boston Scientific Corporation's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on BSX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — BSX SEC Filings

More Tools for BSX

BSX Full Stock Analysis BSX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper BSX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the BSX stock analysis page.

BSX Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer